These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 34925348)
1. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R Front Immunol; 2021; 12():775761. PubMed ID: 34925348 [TBL] [Abstract][Full Text] [Related]
2. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Roulleaux Dugage M; Jones RL; Trent J; Champiat S; Dumont S Front Immunol; 2021; 12():715727. PubMed ID: 34489967 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Sarcoma: Current Data and Promising Strategies. Wood GE; Meyer C; Petitprez F; D'Angelo SP Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557 [TBL] [Abstract][Full Text] [Related]
4. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Sarcoma: Where Do Things Stand? Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140 [TBL] [Abstract][Full Text] [Related]
7. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis. You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583 [No Abstract] [Full Text] [Related]
8. Emerging Targeted and Immune-Based Therapies in Sarcoma. Pollack SM; Ingham M; Spraker MB; Schwartz GK J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291 [TBL] [Abstract][Full Text] [Related]
9. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for sarcomas. Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603 [TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450 [TBL] [Abstract][Full Text] [Related]
13. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034 [TBL] [Abstract][Full Text] [Related]
14. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486 [TBL] [Abstract][Full Text] [Related]
19. Current status of immunotherapy for gastrointestinal stromal tumor. Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088 [TBL] [Abstract][Full Text] [Related]
20. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Liang J; Chen D; Chen L; She X; Zhang H; Xiao Y Future Oncol; 2020 Jun; 16(17):1211-1223. PubMed ID: 32396026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]